Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

<p><strong>Background:</strong> Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.</p> <p><stron...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Horby, PW, Estcourt, L, Peto, L, Emberson, JR, Staplin, N, Spata, E, Cambell, M, Roddick, A, Day, JN, Jeffery, K, Mafham, M, Thwaites, G, Roberts, DJ, Haynes, R, Landray, M, Et al.
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2021

Documenti analoghi

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Horby, P, et al.
Pubblicazione: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Mafham, M, et al.
Pubblicazione: (2021)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Landray, M, et al.
Pubblicazione: (2022)

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
di: Haynes, R, et al.
Pubblicazione: (2023)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Horby, P, et al.
Pubblicazione: (2024)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
di: Horby, PW, et al.
Pubblicazione: (2023)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
di: RECOVERY Collaborative Group, et al.
Pubblicazione: (2022)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Abani, O, et al.
Pubblicazione: (2023)

Allocated but not treated: the silent 16% – Authors' reply
di: Horby, P, et al.
Pubblicazione: (2022)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: Horby, PW, et al.
Pubblicazione: (2021)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
di: RECOVERY Collaborative Group, et al.
Pubblicazione: (2022)

Dexamethasone in hospitalized patients with Covid-19 — preliminary report
di: Horby, P, et al.
Pubblicazione: (2020)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: RECOVERY Collaborative Group, et al.
Pubblicazione: (2021)

Effect of hydroxychloroquine in hospitalized patients with COVID-19
di: Horby, P, et al.
Pubblicazione: (2020)

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
di: Shankar-Hari, M, et al.
Pubblicazione: (2021)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
di: Herrington, W, et al.
Pubblicazione: (2022)

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: RECOVERY Collaborative Group, et al.
Pubblicazione: (2024)

Evidence for the prevention and treatment of stroke in dialysis patients
di: Herrington, W, et al.
Pubblicazione: (2014)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
di: Emberson, JR, et al.
Pubblicazione: (2010)

Making trials part of good clinical care: lessons from the RECOVERY trial
di: Pessoa-Amorim, G, et al.
Pubblicazione: (2021)

Convalescent plasma for Covid-19 - making sense of the inconsistencies
di: Estcourt, L, et al.
Pubblicazione: (2022)

In practice: RECOVERY Trial
di: Horby, P, et al.
Pubblicazione: (2024)

Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial
di: Peto, L, et al.
Pubblicazione: (2022)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
di: RECOVERY Collaborative Group, et al.
Pubblicazione: (2024-01-01)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
di: Mafham, M, et al.
Pubblicazione: (2011)

Hydroxychloroquine for COVID-19: Balancing contrasting claims
di: Horby, PW, et al.
Pubblicazione: (2020)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
di: Zhu, P, et al.
Pubblicazione: (2020)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
di: Staplin, N, et al.
Pubblicazione: (2016)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
di: Zhu, P, et al.
Pubblicazione: (2020)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
di: Harper, C, et al.
Pubblicazione: (2023)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
di: Harper, C, et al.
Pubblicazione: (2021)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
di: Herrington, W, et al.
Pubblicazione: (2016)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
di: Harper, C, et al.
Pubblicazione: (2021)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
di: Reith, C, et al.
Pubblicazione: (2017)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
di: Haynes, R, et al.
Pubblicazione: (2018)

Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
di: Valk, SJ, et al.
Pubblicazione: (2021)

Conventional and genetic evidence on the association between adiposity and CKD
di: Zhu, P, et al.
Pubblicazione: (2020)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
di: Marion Mafham, et al.
Pubblicazione: (2011-01-01)

How should we use convalescent plasma therapies for the management of COVID-19?
di: Wood, EM, et al.
Pubblicazione: (2020)

A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots.
di: Mafham, M, et al.
Pubblicazione: (2007)